Content Reviewed By

Reviewed by a board-certified physician (Medical) · Reviewed by a licensed attorney specializing in mass tort litigation (Legal)

Dupixent Safety Concerns

Residents in can register for updates about safety monitoring related to Dupixent use and cancer diagnoses.

Safety Monitoring in , Indiana

Monitoring includes questions about long-term IL-4/IL-13 pathway inhibition, malignancy risk signals, and whether broader legal action develops.

Indiana Deadline Overview

SOL: 2 years
Rule Type: discovery
View Indiana details

Indiana Attorney General — Consumer Protection

In addition to pursuing a civil lawsuit, residents who experienced harm may file a consumer complaint with the Indiana Attorney General's office:

Todd Rokita, Indiana Attorney General
Consumer Hotline: 1-800-382-5516
Consumer Protection Page →

Filing a consumer complaint creates a public record and may support investigations into manufacturers. Pursuing both channels — AG complaint and civil lawsuit — is recommended.

Federal Court Districts — Indiana

Indiana is served by the following federal judicial district(s). Most Dupixent side effects cases are consolidated in a national MDL, but understanding your local district is useful context:

Northern District of Indiana
Southern District of Indiana

⚖️ Filing Deadline Note: Dupixent (dupilumab) side effect claims are an emerging litigation area. The discovery rule clock typically starts when a provider linked your condition — such as eosinophilic esophagitis, alopecia, or other serious effects — to Dupixent use.